Days after Johnson & Johnson’s posdinemab failed to slow clinical decline in patients with Alzheimer’s disease, Eisai Chief ...

If you are wondering whether Eisai is quietly becoming a value opportunity or just a value trap, you are in the right place to unpack what the current share price is really implying. The stock has ...

If approved, patients could self-administer a weekly dose at home as an alternative to hospital intravenous dosing.

Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate ...

Eisai now has the most detailed look yet at the clinical trial data for its Alzheimer’s disease drug lecanemab, with results showing reductions in telltale disease indicators and a slowing of clinical ...

Eisai officially launched its new U.S. headquarters just as the Japanese pharma looks to expand its commercial presence with an Aduhelm follow-up in Alzheimer’s disease by “building trust with the ...

Eisai (ESALY) and Biogen (BIIB) announced that the latest findings on time savings with continued treatment with humanized ...

Eisai’s work to develop Alzheimer’s drug Leqembi has brought an effective treatment to patients, making it one of Fast Company’s Most Innovative Companies in medicines and therapeutics. For the ...

On Aug. 18, 2022, Eisai Inc. announced the official grand opening of its new headquarters, the Eisai US hhceco Center in Nutley. – EISAI INC. Eisai Inc. held the official grand opening of its new ...

If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the initiation of treatment for this progressive, relentless disease TOKYO and ...

A month after Eisai reported positive, topline phase 3 data of its Alzheimer’s treatment lecanemab, STAT News is out with a new bombshell report that gut-checks the drug’s hype. The health and science ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito) today announced that new data on anti-tau antibody etalanetug ...